1,https://www.reuters.com/article/brief-chemed-corp-q1-revenue-rose-116-to/brief-chemed-corp-q1-revenue-rose-11-6-to-516-million-idUSASA00MCM,2020-04-28T20:25:07Z,BRIEF-Chemed Corp Q1 Revenue Rose 11.6% to $516 Million,April 28 (Reuters) - Chemed Corp:,* Q1 EARNINGS PER SHARE ESTIMATE $3.65 -- REFINITIV IBES DATA,* SAYS ANTICIPATES PROVIDING UPDATED 2020 EARNINGS GUIDANCE IN JULY 2020 Source text for Eikon: Further company coverage:
2,https://www.reuters.com/article/brief-chemed-says-unit-received-802-mln/brief-chemed-says-unit-received-80-2-mln-from-the-provider-relief-fund-idUSFWN2C31BM,2020-04-15T19:17:08Z,BRIEF-Chemed Says Unit Received $80.2 Mln From The Provider Relief Fund,April 15 (Reuters) - Chemed Corp:,"* CHEMED CORP - ON APRIL 10, VITAS HEALTHCARE, UNIT OF CO RECEIVED $80.2 MILLION FROM U.S. FEDERAL GOVERNMENT FROM THE PROVIDER RELIEF FUND Source text: (‍here ) Further company coverage:"
3,https://www.reuters.com/article/brief-chemed-corporations-board-of-direc/brief-chemed-corporations-board-of-directors-authorizes-an-additional-250-million-for-stock-repurchase-idUSASA00HQK,2020-03-13T19:11:40Z,BRIEF-Chemed Corporation’S Board Of Directors Authorizes An Additional $250 Million For Stock Repurchase,Chemed Corp:,* CHEMED CORPORATION’S BOARD OF DIRECTORS AUTHORIZES AN ADDITIONAL $250 MILLION FOR STOCK REPURCHASE,"* CHEMED CORP - REPURCHASES WILL BE FUNDED THROUGH CASH FROM OPERATIONS, REVOLVING CREDIT FACILITY Source text for Eikon: Further company coverage:"
4,https://www.reuters.com/article/brief-chemed-reports-q4-adjusted-earning/brief-chemed-reports-q4-adjusted-earnings-per-share-4-22-idUSASA00DWJ,2020-02-18T21:34:24Z,BRIEF-Chemed Reports Q4 Adjusted Earnings Per Share $4.22,Feb 18 (Reuters) - Chemed Corp:,* Q4 REVENUE $522 MILLION VERSUS REFINITIV IBES ESTIMATE OF $524.2 MILLION,* Q4 EARNINGS PER SHARE ESTIMATE $4.09 -- REFINITIV IBES DATA,* FULL-YEAR 2020 ADJUSTED EARNINGS PER DILUTED SHARE IS ESTIMATED TO BE IN RANGE OF $16.20 TO $16.50,* FY2020 EARNINGS PER SHARE VIEW $15.63 -- REFINITIV IBES DATA,"* REVENUE GROWTH FOR VITAS IN 2020, PRIOR TO MEDICARE CAP, IS ESTIMATED TO BE IN RANGE OF 8.5% TO 9.5%",* ROTO-ROOTER IS FORECASTED TO ACHIEVE FULL-YEAR 2020 REVENUE GROWTH OF 13.0% TO 14.0% Source text for Eikon: Further company coverage:
5,https://www.reuters.com/article/brief-chemed-corp-q1-gaap-earnings-per-s/brief-chemed-corp-q1-gaap-earnings-per-share-2-66-idUSASC09WL3,2018-04-19T20:21:07Z,BRIEF-Chemed Corp Q1 GAAP Earnings Per Share $2.66,April 19 (Reuters) - Chemed Corp:,* Q1 REVENUE $439 MILLION VERSUS I/B/E/S VIEW $419.3 MILLION,* Q1 EARNINGS PER SHARE VIEW $2.36 -- THOMSON REUTERS I/B/E/S,* COMPANY HAS REITERATED EARNINGS GUIDANCE Source text for Eikon: Further company coverage:
